HaiHe Biopharma Co.
Latest round
- Series B
Last raised
- Jul 2020
Total raised
- $172M
Investors
- 12
About HaiHe Biopharma Co.
, Ltd operates as a drug developer that focuses on the development of new drugs for oncology, metabolic diseases and other complex diseases. It has 255 employees, including 158 researchers. Jian Ding, the chairman of the Company, is an academician of the Chinese Academy of Engineering, and is the Vice President of the Chinese Pharmaceutical Society and the Chinese Society of Pharmacology. The company has 121 invention patents and participated in 3 scientific research projects of Chinese Academy of Sciences. In 2018, it established cooperation with Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and enterprises such as Tiger Pharmaceuticals. Its production center was settled in Taizhou Pharmaceutical Hi-tech Zone, with a branch office in America in 2019. The company focuses on the discovery, development, manufacture and commercialization of innovative antitumor drugs. Currently, one of its project, Haiytan was approved for marketing with another 9 products in the pipeline of research and development. Its products within include topoisomerase I inhibitors, oral c-Met selective inhibitors. It also provides services such as quality research, formulation research, pharmacological efficacy evaluation, biomarker discovery and confirmation, medical strategic planning, and clinical research.
Who invested in HaiHe Biopharma Co.
12 investors across 1 round
See all investors in HaiHe Biopharma Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jul 24, 2020
Amount
$172M
Investors
Questions about HaiHe Biopharma Co.
Who invested in HaiHe Biopharma Co.?
HaiHe Biopharma Co. has 12 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HaiHe Biopharma Co. raised?
HaiHe Biopharma Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did HaiHe Biopharma Co. last raise money?
HaiHe Biopharma Co.'s most recent round on record is a Series B, in Jul 2020.
What does HaiHe Biopharma Co. do?
, Ltd operates as a drug developer that focuses on the development of new drugs for oncology, metabolic diseases and other complex diseases.
Where is HaiHe Biopharma Co. headquartered?
HaiHe Biopharma Co. is headquartered in Shanghai, China.
Which VCs invest in companies like HaiHe Biopharma Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at HaiHe Biopharma Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like HaiHe Biopharma Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.